Document is current
Any future updates will be listed below
-
Authors
Capone, Federico https://orcid.org/0000-0001-8127-5564
Häseli, Steffen P. https://orcid.org/0000-0002-8933-3236
Liu, Luo
Strocchi, Stefano
Langenberg, Claudia
Lusis, Aldons J. https://orcid.org/0000-0001-9013-0228
Pietzner, Maik https://orcid.org/0000-0003-3437-9963
Muoio, Deborah M. https://orcid.org/0000-0003-3760-9277
Rider, Oliver J.
Raman, Betty
Fudim, Marat https://orcid.org/0000-0002-8671-7007
Romeo, Stefano
Wang, Yibin https://orcid.org/0000-0003-0852-0767
Völkers, Mirko https://orcid.org/0000-0003-2344-1856
Shah, Svati H.
Schiattarella, Gabriele G. https://orcid.org/0000-0002-7582-7171
- License Information
-
More Information
Article History
Accepted: 26 January 2026
First Online: 23 February 2026
Competing interests
: G.G.S. reports consultancy service and/or has interest in Boehringer Ingelheim, Pfizer, NovoNordisk, e-Therapeutics and Sanofi. M.F. is a consultant and/or has ownership interest in Abbott, Acorai, Ajax, Alio Health, Alleviant, Artha, Astellas, Audicor, AxonTherapies, Bodyguide, Bodyport, Boston Scientific, Broadview, Cadence, Cardiosense, Cardioflow, Clinical Accelerator, CVRx, Daxor, Edwards LifeSciences, Echosens, EKO, Endotronix, Feldschuh Foundation, Fire1, FutureCardia, Gradient, Hatteras, HemodynamiQ, Impulse Dynamics, ISHI, Lumina Health, Medtronic, NovoNordisk, NucleusRx, Omega, Orchestra, Parasym, Pharmacosmos, Presidio, Procyreon, Proton Intelligence, Puzzle, ReCor, Scirent, SCPharma, Shifamed, Splendo, Summacor, SyMap, Terumo, Vascular Dynamics, Vironix, Viscardia and Zoll.
